For example, mammalian cell and bacterially expressed formulation of IFN‐β therapies approved for clinical use, IFN‐β1a and IFN‐β1b, cause systemic toxicities ranging from flu‐like symptoms, myalgia to leukopenia and liver damage.57, 58. Here, IFNB1 is linked to digestive system neoplasm.